Closing Thoughts on the Impact of PSMA-PET Imaging in Prostate Cancer

The safety review committee recommended that the phase 2 portion proceed with the 8 GBq dose.

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

A recap of the FDA submissions and regulatory decisions in urology from February 2025.

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

Myriad is planning to launch its first AI-driven prostate cancer clinical test later this year.

The trial plans to enroll up to 80 adult patients with mCRPC who have progressed on prior systemic therapies.